Overview

A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.

Status:
Not yet recruiting
Trial end date:
2028-05-15
Target enrollment:
Participant gender:
Summary
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Collaborator:
Arvinas Estrogen Receptor, Inc.
Treatments:
Fulvestrant